AbstractThe presence of circulating tumor cells (CTCs) in the blood of cancer patients may guide the use of therapy. We investigated how to evaluate a reduction in the number of CTCs after administration of therapy. CTCs were enumerated with the CellSearch system in 111 metastatic breast and 185 metastatic prostate cancer patients before start of a new line of chemotherapy and after initiation of therapy. Different means to express changes in CTC counts were evaluated with respect to overall survival (OS). A static CTC cutoff is the best method to determine whether a therapy is effective. This is exemplified by the highest Cox hazard ratio of 2.1 for OS; three methods to express relative differences performed worse. A lookup table is provid...
Circulating tumor cells (CTC) in the blood of patients with metastatic carcinomas are associated wit...
Circulating tumor cells (CTCs) were discovered nearly 150 years ago but have only recently been reco...
Purpose Despite the therapeutic advances, disease recurrence remains an ever-present threat to the h...
The presence of circulating tumor cells (CTC) in the blood of cancer patients may guide the use of t...
Circulating tumor cells (CTCs) are cells of presumed epithelial origin, whose prognostic and predict...
Circulating tumor cells (CTCs) can be found in the peripheral blood of metastatic cancer patients. R...
Aim: Attempts have been made to use CTC values for interpretation of treatment response and to guide...
Analysis of circulating tumor cells (CTCs) holds promise to diagnose cancer or monitor its developme...
Circulating tumor cells (CTCs) are cancer cells that are present in the blood of patients with solid...
International audienceThe aim of this study was to investigate whether the enumeration of circulatin...
Treatment response biomarkers are urgently needed for castration-resistant prostate cancer (CRPC). B...
Circulating tumor cells (CTCs) can be detected in the blood of different types of early or advanced ...
Abstract PURPOSE: Presence of circulating tumor cells (CTC) in metastatic carcinoma is associated wi...
International audienceThe prognostic role of circulating tumor cells (CTCs) has been clearly demonst...
Given the low specificity of the routinely used biomarker prostate-specific antigen, circulating tum...
Circulating tumor cells (CTC) in the blood of patients with metastatic carcinomas are associated wit...
Circulating tumor cells (CTCs) were discovered nearly 150 years ago but have only recently been reco...
Purpose Despite the therapeutic advances, disease recurrence remains an ever-present threat to the h...
The presence of circulating tumor cells (CTC) in the blood of cancer patients may guide the use of t...
Circulating tumor cells (CTCs) are cells of presumed epithelial origin, whose prognostic and predict...
Circulating tumor cells (CTCs) can be found in the peripheral blood of metastatic cancer patients. R...
Aim: Attempts have been made to use CTC values for interpretation of treatment response and to guide...
Analysis of circulating tumor cells (CTCs) holds promise to diagnose cancer or monitor its developme...
Circulating tumor cells (CTCs) are cancer cells that are present in the blood of patients with solid...
International audienceThe aim of this study was to investigate whether the enumeration of circulatin...
Treatment response biomarkers are urgently needed for castration-resistant prostate cancer (CRPC). B...
Circulating tumor cells (CTCs) can be detected in the blood of different types of early or advanced ...
Abstract PURPOSE: Presence of circulating tumor cells (CTC) in metastatic carcinoma is associated wi...
International audienceThe prognostic role of circulating tumor cells (CTCs) has been clearly demonst...
Given the low specificity of the routinely used biomarker prostate-specific antigen, circulating tum...
Circulating tumor cells (CTC) in the blood of patients with metastatic carcinomas are associated wit...
Circulating tumor cells (CTCs) were discovered nearly 150 years ago but have only recently been reco...
Purpose Despite the therapeutic advances, disease recurrence remains an ever-present threat to the h...